Background: Evidence is plentiful that trans fatty acids (TFAs) induce vascular inflammation with adverse metabolic consequences. However, it is not clear whether TFAs increase the risk of vascular pregnancy complications such as preeclampsia.
Introduction
Poor intrauterine growth and preterm birth significantly increase the risks of perinatal, infant, and childhood mortality and morbidity (1, 2) . Therefore, to achieve substantial improvements in pregnancy outcomes the identification of risk factors is crucial.
The prenatal phase is characterized by rapid growth and numerous cell divisions, and therefore it is also an extremely sensitive period for nutritional influences (3) . In adults, the consumption of trans FAs (TFAs) 10 has contributed to unfavorable health effects, such as an elevated risk of coronary artery disease (4) . Because it has been demonstrated that TFAs can pass the placenta, and that substantial amounts are transferred from mother to fetus (5, 6) , the safety of these dietary intakes during pregnancy is being questioned (7) . Various (patho)physiological effects including pro-inflammation, oxidative stress, and endothelial dysfunction have been related to these fats in particular (7, 8) . Continued research aiming to investigate the effects of TFAs on perinatal health, however, remains inconclusive (9) (10) (11) (12) .
Considering the vascular similarities in pathogenesis with coronary artery disease, as well as the presumed metabolic consequences of TFA consumption, TFAs are suspected to increase the risk of vascular pregnancy complications such as preeclampsia, but so far are controversial (13, 14) .
In the Generation R birth cohort (Netherlands, 2001 (Netherlands, -2005 , we investigated associations of maternal midpregnancy plasma trans 18:1 FA (t18:1) concentrations with birth weight, placental weight, and maternal pregnancy-induced hypertension (PIH) and preeclampsia. Also, we explored potential time trends across birth years in the association of maternal plasma t18:1 concentrations on birth weight, given a Dutch industry-initiative to lower TFA food content during the inclusion period (12) . After a major reduction of TFA concentrations in the food supply during the 1990s, a second round of actions to lower the TFA food content took place. In 2003, a collaboration of trade and production companies in the Netherlands targeted the edible oils and fats chain and tackled the use of TFAs in frying oils, fast foods, and baked goods (12) .
Considering that no safe concentrations of TFA intake can be given based on the existing scientific evidence (15), we hypothesize that associations between maternal plasma t18:1 concentrations and increased risk of vascular-related pregnancy complications in mother and newborns persist at low maternal t18:1 intakes.
Methods
Design and study population. The current study is embedded in the Generation R Study. The Generation R Study, a prospective birth cohort study among pregnant women included between 2001 and 2005 (births in [2002] [2003] [2004] [2005] [2006] , was designed to identify early environmental and genetic determinants of growth, development, and health and has been described in detail (16) . FA analyses were obtained in 7069 of 8690 mothers (81%) at <25 wk of gestation. In 6695 mother-infant pairs, information on birth weight, gestational age at birth, and year of infant birth was available for analyses (Supplemental Figure 1) .
Information on PIH and preeclampsia was present for 6168 motherinfant pairs. Because growth potentials for the individual fetus in multiple pregnancies are not comparable to singleton pregnancies, we excluded twin pregnancies (n = 133) for analyses of birth weight and placental weight.
Written informed consent was obtained from all participants. The study was approved by the Medical Ethics Committee of the Erasmus Medical Center.
TFA analysis in midpregnancy maternal plasma. t18:1 Isomers are most abundant in the Western diet and they account for ;80-90% of total TFA intake (13) . The measurement of the maternal plasma FA concentrations has been described previously (17) . For the current study, plasma t18:1 concentrations are expressed as percentage of weight (wt:wt%) of the total FA concentrations.
Assessment of gestational age, birth weight, placental weight, and pregnancy complications. The methods for establishing gestational age and standard ultrasound planes for fetal measurements have been described previously (18) . Inter-and intraobserver intraclass correlation coefficients were all >0.98 (18) . Information on birth weight, placental weight, and gestational duration was obtained from community midwifery and hospital registries. Birth weight and placental weight were measured directly postpartum and expressed in kilograms. Each placenta was weighed immediately after delivery and included the membranes and umbilical cord. Placental ratio was calculated as (placental weight/birth weight) 3 100. To disentangle the effects of birth weight from gestational age we expressed birth weight in units adjusted for gestational age and sex: the birth weight SD score. The birth weight SD scores were constructed based on distributions in the Generation R cohort (19) . The analyses with placental weight were adjusted for gestational duration. Infants born small-for-gestational age (SGA) were defined as a gestational-age-adjusted birth weight <10th percentile (21.4 SD score) in the study cohort.
The data collection regarding the development of preeclampsia and PIH has been described previously (20) . Briefly, the following criteria were used to identify women with PIH: systolic blood pressure $140 mm Hg and/or diastolic blood pressure $90 mm Hg after 20 wk of gestational age in previously normotensive women. These criteria in the presence of proteinuria (defined as 2 or more dipstick readings of $2, one catheter sample reading of $1, or a 24-h urine collection containing at least 300 mg protein) were used to identify women with preeclampsia (21) .
Covariates. Potential confounders of the association between maternal plasma t18:1 concentrations and birth weight were derived from the literature (10) .
At enrollment [median (IQR) gestational age: 14.1 wk (11.8, 16.4 wk)], we obtained by questionnaires information on maternal age, national origin, educational level, parity, prenatal smoking, alcohol use, and folic acid supplement use. National origin of the mother was based on the country of birth of the parents and categorized as Dutch, other Western, and non-Western. Educational level of the pregnant woman was assessed by the highest completed education and categorized as primary school only, secondary school, or higher education. Maternal prenatal smoking and alcohol use were classified as no use, use until pregnancy was confirmed, and continued use during pregnancy. Folic acid supplement use was classified as no use, use started during the first 10 wk of pregnancy, or use started preconceptionally. Maternal BMI (in kg/m 2 ) was calculated by using weight (kilogram) and height (centimeter) measured at enrollment because of validity reasons and the very high correlation between early pregnancy BMI and self-reported prepregnancy BMI (Pearson correlation 0.95; P < 0.001).
At 20 wk of pregnancy, we measured maternal psychological symptoms using the Brief Symptom Inventory (22) . Infant sex was derived from medical records completed by midwives and gynecologists. Maternal hemoglobin and hematocrit concentrations were measured in fresh EDTA plasma samples in venous blood samples at enrollment (STAR-MDC) (23) .
Statistical analysis. In our analyses, the maternal midpregnancy plasma t18:1 concentration was used as a continuous determinant. Multivariable linear regression models were used for analyzing continuous outcome variables. Dichotomous outcome variables were analyzed by using logistic regression models.
In a first step, we studied associations between maternal plasma t18:1 concentrations with birth weight and placental weight. In addition, we tested the association between maternal plasma t18:1 concentrations and SGA using logistic regression analyses. Next, associations between maternal plasma t18:1 concentrations and the risk of PIH and preeclampsia were studied.
Second, given the Dutch industry-initiative to lower TFA food content during the inclusion period, we explored potential time trends of the association with birth weight.
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with results from a survey after TFA food content in the same period by the Dutch Task Force for Responsible Fatty Acid Composition (24) .
Subsequently, in a third step we tested whether any association between maternal plasma t18:1 concentration and birth weight was moderated by year of infant birth. We therefore standardized the maternal midpregnancy plasma t18:1 concentration per birth-year cohort to create a relative measure. This standardized plasma t18:1 concentration variable was entered as an interaction term with infant birth year into the model.
Because dietary intake of TFAs may differ between ethnic subgroups, we additionally reran the analyses among women of Dutch national origin (n = 3499, 50.5%), i.e., the largest ethnic subgroup. We also evaluated data on maternal plasma trans 18:2 FA (t18:2) and trans 16:1 FA (t16:1) concentrations and compared findings with t18:1.
TFAs in plasma are suggested to interfere with essential FA plasma concentrations. Therefore, we examined associations between maternal plasma t18:1 concentrations and arachidonic acid (AA) and DHA plasma concentrations and tested whether these n-3 and n-6 long-chain FAs explained any association between plasma t18:1 concentration and the various pregnancy outcomes.
Plasma concentrations could be a reflection of hemodilution due to expansion of plasma volume. High hemoglobin values are associated with placental infarction and impaired fetal growth, as previously reported in the current cohort (25) . To explore the possibility of confounding by variability in the degree of plasma volume expansion across gestation, we additionally adjusted the analyses for hemoglobin and hematocrit concentrations.
To test robustness, analyses were rerun after exclusion of children born preterm (<37 wk of gestation) or mothers with diabetes mellitus or diabetes gravidarum.
Missing data were handled in 2 ways: for categorical variables, the missing value was recoded as a dummy variable; for continuous variables, the missing item was replaced by the mean value. All analyses were adjusted for potential confounders. Analyses were performed by using SPSS software, version 21.0 (IBM-SPSS).
Results
Characteristics of the mothers and infants in the study are presented in Table 1 .
The plasma concentrations of t18:2 and t16:1 were substantially lower than of t18:1 (median 6 SD: t18:1, 3.31 6 1.79 mg/L; t18:2, 1.09 6 0.41 mg/L; and t16:1, 0.89 6 0.30 mg/L).
These TFA isomers did not decrease during the period tested and were not associated with any of the outcome variables after correction for confounders (results not shown). Therefore, plasma t18:2 and t16:1 concentrations were not further investigated.
A higher maternal midpregnancy plasma t18:1 concentration was associated with a lower birth weight and placental weight and not with the placenta-birth weight ratio ( Table 2) . The change per increase in unit of wt:wt% plasma t18:1 concentration equals a decrease of 58 g in birth weight at term.
Likewise, a higher maternal midpregnancy plasma t18:1 concentration was associated with a higher risk of SGA (for all women, adjusted OR: 1.31; 95% CI: 1.07,1.60; P = 0.01; for Dutch women, adjusted OR: 1.22; 95% CI: 0.86, 1.73; P = 0.27; other results not shown). Table 3 shows that a higher maternal midpregnancy plasma t18:1 concentration was also associated with a higher risk of preeclampsia but not PIH. Figure 1 presents the median maternal plasma t18:1 concentrations measured in midpregnancy per year of infant birth. Between 2001 and 2005, the plasma t18:1 concentration decreased from a median of 3.87 mg/L (95% range: 1.89-7.82 mg/L) to 2.47 mg/L (95% range:1.43-4.73 mg/L) ( Figure  1A ). This reduction is in line with the reduction of the TFA food content during the same period measured in a survey by the Task Force for Responsible Fatty Acid Composition ( Figure 1B) (24) .
In Table 4 we present the results of a moderation analysis of the association of plasma t18:1 concentration with birth weight over time. The association between birth weight with relative levels of TFA did not change over time.
The results were essentially the same when data from children born preterm or women with diabetes mellitus or diabetes gravidarum were excluded from the analyses (data not shown).
Maternal midpregnancy plasma t18:1 concentration was inversely associated with maternal AA (AA wt:wt%: adjusted b 23.75; 95% CI: 25.62, 21.88; P < 0.001) and DHA (DHA Early maternal pregnancy hematocrit levels were positively related to the midpregnancy plasma t18:1 concentration (hematocrit adjusted b: 0.79; 95% CI: 0.37, 1.21; P < 0.001). Hemoglobin levels did not show a significant association with the plasma t18:1 concentration (adjusted b: 0.02; 95% CI: 20.03, 0.04; P = 0.10). Adjusting the analyses of plasma t18:1 concentration and birth outcomes for hematocrit levels and hemoglobin levels however did not materially change the results (results not shown).
Discussion
This population-based study shows that a higher maternal midpregnancy plasma t18:1 concentration was associated with a lower birth weight and placental weight and a higher risk of preeclampsia. During the study period 2001-2005, we observed a 31% lower median maternal plasma t18:1 concentration in midpregnancy, which corresponds well with the lower TFA food content as a result of a Dutch industry initiative. Despite the decrease in TFA intake, the inverse association between the maternal plasma t18:1 concentration and birth weight however remained.
Previous research on the association between maternal TFA intakes and child birth weight showed mixed results. In premature infants cord plasma t18:1 concentration was inversely related to birth weight (9) . In another Dutch birth cohort, van Eijsden et al. (10) observed a lower birth weight and doubled risk of SGA in mothers with the most adverse plasma n-3, n-6, and t18:1 FA concentrations. The work of Elias and Innis (6) showed an inverse association between maternal TFA concentrations and gestational duration but not birth weight.
The mechanism by which TFA isomers influence perinatal health outcomes remains elusive. Because outcomes might reflect vascular functioning during pregnancy, the findings from the extensive literature regarding TFA and the mechanism of cardiovascular disease in adults might also apply for perinatal health. TFAs are powerful modulators of cell function, altering membrane fluidity and responses of membrane receptors by means of their incorporation into the phospholipids in cellular membranes (26) . Several researchers suggest that not the atherogenic effect of TFAs but the potential interference of TFAs with the availability of essential FAs are of main importance for perinatal health (27) . Therefore, TFA intake could be considered an indirect marker of low dietary essential FA intake. In the current study, we describe an inverse relation between concentrations of maternal plasma t18:1 and the essential FAs AA and DHA, even after adjustment for potential socioeconomic confounders. However, lower concentrations of these long-chain FAs did not explain the associations between plasma t18:1 concentrations and pregnancy outcomes.
Although we observed a reduction in maternal midpregnancy plasma t18:1 concentration over time, its associations with pregnancy outcomes did not change in parallel.
In the Danish National Birth Cohort, dietary TFA intakes estimated based on food frequency questionnaires could not be related to the risk of preeclampsia after the national reduction of TFA in food products (28) . To our knowledge, no studies investigated prospectively the relation between the reduction of TFAs in foods and the risk of vascular-related pregnancy 2 To approximate normal distribution, maternal midpregnancy plasma t18:1 concentration (wt:wt%) was transformed by the natural logarithm. 3 Gestational age at birth-adjusted and sex-adjusted birth weight SD score. 4 Adjusted for gestational age at blood sampling. 5 Fully adjusted analyses are adjusted for gestational age at blood sampling, maternal age, parity, educational level, national origins (all women only), BMI, height, alcohol use, smoking, folic acid supplement use, and psychological symptoms. outcomes by using midpregnancy maternal TFA plasma concentrations as biomarkers. One Australian case-control study measured TFA concentrations in adipose tissue in 79 cases of nonfatal myocardial infarction and 167 matched controls (29) . The results showed that, after the amount of TFAs was reduced from margarines, the observed associations between TFA concentrations in adipose tissue and the risk of nonfatal myocardial infarction were less strong. The absence of a time trend raises several possibilities for interpretation. First, during the study period, TFA intakes were generally already low because a major reduction in TFA food content in the Netherlands took place over a decade before enrollment. In addition, the effects of the reduction of maternal TFA concentration may be too small to change the association.
Second, our assessment of the FA concentrations was based on a single measure in blood in midpregnancy, which might not be reliable enough to reflect the maternal FA status in the second and early third trimester of pregnancy. However, repeated measurements were not feasible in this large population-based study. Furthermore, other nutrients, such as vitamin A, vitamin E, and iron, that are associated with TFA intake as well as birth weight and vascular-related pregnancy complications were not investigated (30, 31) . In Canada, TFAs were mainly replaced by PUFAs (32) . However, if the reformulation in the Netherlands led to an increased intake of other potential detrimental nutrients, the beneficial effects on pregnancy outcomes would be less marked than expected.
Finally, a relatively higher maternal TFA plasma concentration is associated with the intake of certain food products, including bakery products, snacks, and fast foods (33) . This may suggest that TFAs, at least partly, are also considered a marker of lifestyle rather than a directly harmful exposure. However, we should be cautious because the absence of moderation does by no means prove that TFAs are not a risk factor.
The major strength of the present study is that it took advantage of a natural experiment of an industry initiative to lower TFA food content during the years in which we obtained maternal blood samples during pregnancy. Other strengths include prospective measures of exposure and outcome and the availability of data on important confounding factors.
Nevertheless, several limitations should be considered in the interpretation of our data. First, because maternal plasma t18:1 concentrations were measured in midpregnancy, we might not have assessed this biomarker at the most relevant periconceptional period in which most pregnancy complications originate (34) . Early placentation events are considered initiators of both preeclampsia and fetal growth restriction. However, others have found that the overall composition of diet in general and intake of TFAs in particular hardly change between the first and second trimester of pregnancy (35) , suggesting that this limitation may not have influenced our results meaningfully.
Another limitation might be the use of all isomeric plasma t18:1 concentrations combined as a determinant without distinguishing between the specific isomers. The plasma t18:1 concentrations measured in the current study compromise several industrial and ruminant isomers. Because of distinct differences in the isomeric distribution of TFAs from industrial or ruminant sources, differential effects on health outcomes have been suggested. However, clinical studies exploring the effects of ruminant TFAs are scarce (36) .
Finally, because of the observational study design we cannot rule out that the observed associations are the result of residual confounding from sociodemographic and lifestyle-related determinants. In conclusion, a higher maternal midpregnancy plasma t18:1 concentration was associated with a lower birth weight, lower placental weight, and higher risk of SGA and preeclampsia. Voluntary industry initiatives to lower TFA food content showed beneficial effects on maternal plasma t18:1 concentrations in our population over time. Although the intake of TFA in our population decreased during the inclusion period, the association with adverse pregnancy outcomes was unchanged even at lower maternal plasma t18:1 concentrations.
